Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer.

  title={Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer.},
  author={Anthony Maraveyas and Justin Waters and Rajarshi Roy and David Fyfe and David J. Propper and Fiona J Lofts and Joseph Sgouros and E Gardiner and Kate Wedgwood and Camille Ettelaie and George Bozas},
  journal={European journal of cancer},
  volume={48 9},
BACKGROUND Annualised figures show an up to 7-fold higher incidence of vascular thromboembolism (VTE) in patients with advanced pancreatic cancer (APC) compared to other common malignancies. Concurrent VTE has been shown to confer a worse overall prognosis in APC. METHODS One hundred and twenty three APC patients were randomised to receive either gemcitabine 1000 mg/m(2) or the same with weight-adjusted dalteparin (WAD) for 12 weeks. Primary end-point was the reduction of all-type VTE during… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS

From This Paper

Topics from this paper.
66 Citations
0 References
Similar Papers


Publications citing this paper.
Showing 1-10 of 66 extracted citations

Similar Papers

Loading similar papers…